{"id":7269,"date":"2005-06-15T11:32:43","date_gmt":"2005-06-15T10:32:43","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=7269"},"modified":"2014-05-21T17:49:11","modified_gmt":"2014-05-21T17:49:11","slug":"fda-approve-entecavir-for-hbv","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/7269","title":{"rendered":"FDA approve entecavir for HBV"},"content":{"rendered":"<p><strong>On March 29, 2005, FDA approved entecavir (Baraclude) for the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication, and either evidence of persistent elevations in serum aminotransferases (ALT or AST), or histologically active disease.<\/strong><\/p>\n<p>This indication is based on histologic, virologic, biochemical, and serologic responses after one year of treatment in nucleoside-treatment-naive and lamivudine-resistant adult patients with HBeAg*-positive, or HBeAg-negative chronic HBV infection with compensated liver disease, and on more limited data in adult patients with HIV\/HBV co-infection who have received prior lamivudine therapy.<\/p>\n<p>Limited data about entecavir in patients with HIV\/HBV co-infection who received prior lamivudine therapy are presented in the label. Please refer to the label and the Special Population section under Description of Clinical Studies for information on HIV\/HBV co-infected patients.<\/p>\n<p>Source: FDA listserve, March 2005<\/p>\n","protected":false},"excerpt":{"rendered":"<p>On March 29, 2005, FDA approved entecavir (Baraclude) for the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication, and either evidence of persistent elevations in serum aminotransferases (ALT or AST), or histologically active &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-7269","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/7269","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=7269"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/7269\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=7269"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=7269"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=7269"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}